Corporate Profile:
Daiichi Sankyo Group is a Global Healthcare Leader and the 2nd largest pharmaceutical company in Japan. Its regional headquarter, Daiichi Sankyo (China) Holdings Co., Ltd., established in Shanghai in 2011, orchestrates strategic investments and operational excellence across its China’s subsidiaries. With 1,500+ employees nationwide and a state-of-the-art manufacturing facility in Shanghai, the organization drives innovation in oncology, cardiovascular care, and anti-infective therapies. As a pioneer in antibody-drug conjugate (ADC) therapeutics, Daiichi Sankyo’s global oncology pipeline, with breakthrough treatments for breast, gastric, and lung cancers, positions China as a pivotal growth market under its Vision 2030 to become a "sustainable innovation-driven global healthcare leader."
Daiichi Sankyo Group is a Global Healthcare Leader and the 2nd largest pharmaceutical company in Japan. Its regional headquarter, Daiichi Sankyo (China) Holdings Co., Ltd., established in Shanghai in 2011, orchestrates strategic investments and operational excellence across its China’s subsidiaries. With 1,500+ employees nationwide and a state-of-the-art manufacturing facility in Shanghai, the organization drives innovation in oncology, cardiovascular care, and anti-infective therapies. As a pioneer in antibody-drug conjugate (ADC) therapeutics, Daiichi Sankyo’s global oncology pipeline, with breakthrough treatments for breast, gastric, and lung cancers, positions China as a pivotal growth market under its Vision 2030 to become a "sustainable innovation-driven global healthcare leader."
Challenges:
1. Constantly Changing Budget Targets and Assumptions
Frequent policy shifts and market volatility necessitated multi-version scenario-based budgeting, escalating complexity and difficulty in financial planning
2. Fragmented Data Ecosystems
Decentralized data standards across departments caused error-prone manual reconciliations, delaying critical decision timelines by 30-45 days quarterly
3. Resource-Intensive Forecasting Cycles
Quarterly rolling forecasts consumed 500+ person-hours monthly, diverting strategic focus from core R&D and commercialization priorities
4. Analytical Infrastructure Gaps
Legacy systems lacked multi-dimensional reporting capabilities, requiring costly custom development to meet dual compliance standards (local GAAP and Japan HQ requirements)
5. Intercompany Settlement Bottlenecks
Manual allocation of $150M+ annual intra-group service charges hampered financial close processes, risking audit non-compliance across 20+ entity-level reports.
Solution:
Next-Generation Comprehensive Budgeting Platform
Partnering with EVOX, Daiichi Sankyo (China) implemented an enterprise-wide financial transformation solution featuring:
Agile Budgeting Framework
• Scenario-based modeling supporting 12+ regulatory/competitive hypotheses
• Real-time KPI adjustments aligned with Chinese dynamic healthcare policies
Unified Data Governance
• Centralized master data repository with ISO 8000-compliant standards
• Automated cross-departmental data validation workflows
Intelligent Forecasting Engine
• 70% reduction in quarterly rolling forecast cycles via AI-driven predictive analytics
• Dynamic resource allocation algorithms optimizing R&D OPEX efficiency
Advanced Analytics Platform
• Self-service multi-dimensional reporting (product/region/therapeutic area views)
• Dual-compliance reporting templates reducing localization efforts by 40%
Automated Intercompany Reconciliation
• System auto settlement, resolving 95% of intra-group disputes pre-close
• Unified P&L statements across multiple reporting dimensions, e.g., entity, product, project, region, function, etc.
Quantifiable Business Impact
• 45% faster budget cycles enabling rapid response to NMPA policy changes
• 99.2% data accuracy across financial statements through automated controls
• $2.1M annual savings from reduced manual reconciliation efforts
• 360° profitability insights driving 15% portfolio optimization in oncology investments
• 30% acceleration in month-end close meeting both CSRC and J-GAAP requirements
Next-Generation Comprehensive Budgeting Platform
Partnering with EVOX, Daiichi Sankyo (China) implemented an enterprise-wide financial transformation solution featuring:
Agile Budgeting Framework
• Scenario-based modeling supporting 12+ regulatory/competitive hypotheses
• Real-time KPI adjustments aligned with Chinese dynamic healthcare policies
Unified Data Governance
• Centralized master data repository with ISO 8000-compliant standards
• Automated cross-departmental data validation workflows
Intelligent Forecasting Engine
• 70% reduction in quarterly rolling forecast cycles via AI-driven predictive analytics
• Dynamic resource allocation algorithms optimizing R&D OPEX efficiency
Advanced Analytics Platform
• Self-service multi-dimensional reporting (product/region/therapeutic area views)
• Dual-compliance reporting templates reducing localization efforts by 40%
Automated Intercompany Reconciliation
• System auto settlement, resolving 95% of intra-group disputes pre-close
• Unified P&L statements across multiple reporting dimensions, e.g., entity, product, project, region, function, etc.
Quantifiable Business Impact
• 45% faster budget cycles enabling rapid response to NMPA policy changes
• 99.2% data accuracy across financial statements through automated controls
• $2.1M annual savings from reduced manual reconciliation efforts
• 360° profitability insights driving 15% portfolio optimization in oncology investments
• 30% acceleration in month-end close meeting both CSRC and J-GAAP requirements
A New Era of Financial Agility
This transformation establishes Daiichi Sankyo (China) as a benchmark for pharmaceutical financial innovation. By integrating predictive analytics, regulatory intelligence, and cross-border compliance automation, the organization now operates with:
• Real-time visibility into $800M+ regional OPEX
• Dynamic risk-adjusted ROI modeling for 50+ pipeline assets
• Collaborative workflows bridging Shanghai HQ with 18 regional subsidiaries
As Daiichi Sankyo advances its mission to deliver "world-class healthcare solutions," this strategic financial infrastructure positions the organization to lead China’s $140B oncology market while accelerating global ADC therapeutic breakthroughs.
Why Industry Leaders Choose EVOX
EVOX empowers organizations to lead with confidence, scale with speed, and innovate with resilience:
• Proven at Scale: Over 500 successful deployments across 20+ industries, e.g., retail, manufacturing, pharmaceutical, banking & finance, auto, service sectors, etc.
• Future-Proof Architecture: Cloud-agnostic deployment supports hybrid and multi-cloud environments, aligns with organizations’ evolving IT strategies
• Investor-Validated Excellence: Backed by IDG Capital, Sequoia China, and other leading global investors with over $60M in total funding, underscoring our long-term commitment to innovation and customer success
This transformation establishes Daiichi Sankyo (China) as a benchmark for pharmaceutical financial innovation. By integrating predictive analytics, regulatory intelligence, and cross-border compliance automation, the organization now operates with:
• Real-time visibility into $800M+ regional OPEX
• Dynamic risk-adjusted ROI modeling for 50+ pipeline assets
• Collaborative workflows bridging Shanghai HQ with 18 regional subsidiaries
As Daiichi Sankyo advances its mission to deliver "world-class healthcare solutions," this strategic financial infrastructure positions the organization to lead China’s $140B oncology market while accelerating global ADC therapeutic breakthroughs.
Why Industry Leaders Choose EVOX
EVOX empowers organizations to lead with confidence, scale with speed, and innovate with resilience:
• Proven at Scale: Over 500 successful deployments across 20+ industries, e.g., retail, manufacturing, pharmaceutical, banking & finance, auto, service sectors, etc.
• Future-Proof Architecture: Cloud-agnostic deployment supports hybrid and multi-cloud environments, aligns with organizations’ evolving IT strategies
• Investor-Validated Excellence: Backed by IDG Capital, Sequoia China, and other leading global investors with over $60M in total funding, underscoring our long-term commitment to innovation and customer success
About EVOX
EVOX (owned by Espero Technology Pte. Ltd.) is the AI-powered Enterprise Performance Management platform, designed to seamlessly connect Data, Business Scenarios, and People to evolve organizations toward excellence. EVOX platform is featuring EVOX Budgeting & Planning, EVOX Consolidation, and EVOX SPM, empowers enterprises to:
• Reduce monthly close cycles by over 40%
• Elevate forecasting accuracy by over 95% confidence levels
• Achieve 100% audit-compliant financial consolidation
Headquartered in Singapore with worldwide business coverage, EVOX continues to redefine EPM for organizations.
EVOX (owned by Espero Technology Pte. Ltd.) is the AI-powered Enterprise Performance Management platform, designed to seamlessly connect Data, Business Scenarios, and People to evolve organizations toward excellence. EVOX platform is featuring EVOX Budgeting & Planning, EVOX Consolidation, and EVOX SPM, empowers enterprises to:
• Reduce monthly close cycles by over 40%
• Elevate forecasting accuracy by over 95% confidence levels
• Achieve 100% audit-compliant financial consolidation
Headquartered in Singapore with worldwide business coverage, EVOX continues to redefine EPM for organizations.